Advanced search
Publication Cover
Patient Related Outcome Measures Volume 7, 2016 - Issue
Submit an article Journal homepage
112
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort

Matthew F Sidovar1 Clinical Development and Medical Affairs, Acorda Therapeutics, Ardsley, NY
,
Brendan L Limone2 Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA
&
Craig I Coleman2 Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USACorrespondence[email protected]
Pages 13-18 | Published online: 03 Feb 2016

References

  • WaxmanSGConduction in myelinated, unmyelinated, and demyelinated fibersArch Neurol19773410585589907529
  • SmithKJMcDonaldWIThe pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the diseasePhilos Trans R Soc Lond B Biol Sci199935413901649167310603618
  • SutliffMContribution of impaired mobility to patient burden in multiple sclerosisCurr Med Res Opin201026110911919916707
  • SalterARCutterGRTyryTMarrieRAVollmerTImpact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MSCurr Med Res Opin201026249350020014979
  • LaRoccaNImpact of walking impairment in multiple sclerosis: perspectives of patients and care partnersPatient20114318920121766914
  • DakinHReview of studies mapping from quality of life or clinical measures to EQ-5D: an online databaseHealth Qual Life Outcomes20131115124010873
  • EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy199016319920810109801
  • SidovarMFLimoneBLLeeSColemanCIMapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patientsBMJ Open201335e002798
  • YapundichRApplebeeABethouxFEvaluation of dalfampridine extended release 5 and 10 mg in MS; a randomized, controlled trialInt J MS Care201517313814526052259
  • BrooksREuroQol: the current state of playHealth Policy1996371537210158943
  • ShawJWJohnsonJACoonsSJUS valuation of the EQ-5D health states: development and testing of the D1 valuation modelMed Care200543320322015725977
  • HobartJCRiaziALampingDLFitzpatrickRThompsonAJMeasuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12)Neurology2003601313612525714
  • LongworthLRowenDNational Institute for Health and Clinical Excellence (NICE) Decision Support Unit (DSU)Technical Support Document 10: The use of mapping methods to estimate health state utility values Available from: http://www.nicedsu.org.uk/TSD%2010%20mapping%20FINAL.pdfAccessed September 5, 2015
  • RowenDBrazierJRobertsJMapping SF-36 onto the EQ-5D index: how reliable is the relationship?Health Qual Life Outcomes200972719335878
  • HawtonAGreenCTelfordCWrightDZajicekJThe use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5DMult Scler201218685386122108867
  • LimoneBLSidovarMFColemanCIEstimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patientsHealth Qual Life Outcomes20131110523799913
  • HobartJCanoSIngramWZajicekJA new path for the MS Walking Scale: MSWS-12 version 2Mult Scler2012184334335

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.